Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion

This article was originally published in PharmAsia News

Executive Summary

Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies
Advertisement

Related Content

From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India
From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India
Takeda Takes Global Expansion Next Door To South Korea
Takeda Takes Global Expansion Next Door To South Korea
Takeda Partner Santhera Commences Phase III Trial For Duchenne Muscular Dystrophy Drug
Takeda Partner Santhera Commences Phase III Trial For Duchenne Muscular Dystrophy Drug
Astellas/Pfizer’s COX-2 Inhibitor Celecox Gains Additional Indications In Japan
Takeda Halts Development Of Diabetes Agent TAK-379
Takeda Starts Japanese Fiscal Year With Global Reorganization
Takeda Starts Japanese Fiscal Year With Global Reorganization
Advertisement
UsernamePublicRestriction

Register

SC071302

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel